Previous 10 | Next 10 |
Atara Biotherapeutics, Inc. (ATRA) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - Chief Financial Officer Jakob Dupont - EVP and Global Head of Research and Development AJ J...
Atara Biotherapeutics press release (NASDAQ:ATRA): Q1 GAAP EPS of -$0.87 beats by $0.14. Revenue of $7.31M (+105.9% Y/Y) beats by $2.98M. For further details see: Atara Biotherapeutics GAAP EPS of -$0.87 beats by $0.14, revenue of $7.31M beats by $2.98M
FDA Fast-Track Designated ATA188 Interim Analysis On-Track for June 2022 Tab-cel Anticipated European Commission Approval On-Track for Q4 2022; Dialogue with FDA Ongoing Cash Expected to Fund Planned Operations into Q4 2023 with Sale of Cell Therapy Manufacturing Facil...
Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded today at $54.45, eclipsing its 52-week high. Approximately 42.6 million shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares. In the past 52 weeks, Atara Biotherapeutics Inc. share prices ...
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded today at $54.45, eclipsing its 52-week high. So far today approximately 42.6 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Atara Biotherapeutics Inc operates in the United State...
Atara Biotherapeutics (NASDAQ:ATRA) appoints biopharma executive Charlene Banard as its new chief technical officer. Banard comes to Atara from Novartis, where, as Global Head, Technical Operations, Cell & Gene Therapy Platform, she led C> lifecycle management strategy and...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announces biopharmaceutical executive Charlene Banard will jo...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of ...
Scientific Experts Join Atara Management Team to Discuss Role of EBV in MS and Clinical Development of ATA188 Live Conference Call and Webcast on March 22 at 4:00 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging it...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...